UK markets open in 49 minutes

Onxeo SA (0NWK.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
1.2790+0.5485 (+75.09%)
At close: 4:45PM GMT

Onxeo SA

49, boulevard du GEnEral Martial Valin
Paris 75015
France
33 1 45 58 76 00
http://www.onxeo.com

Sector(s)
Industry
Full-time employees30

Key executives

NameTitlePayExercisedYear born
Ms. Judith GrecietCEO & Director455.5kN/A1968
Mr. Nicolas FellmannCFO & Admin. and Fin. DirectorN/AN/A1968
Dr. Françoise Bono Ph.D.Chief Scientific OfficerN/AN/AN/A
Ms. Audrey Legentil-DumeryDirector of HRN/AN/AN/A
Mr. Michel ForestChief Pharmacist & Quality Assurance DirectorN/AN/AN/A
Mr. Philippe M. MaitreChief of US Operations & Exec. VPN/AN/A1957
Dr. Olivier de Beaumont M.D., MBAChief Medical OfficerN/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of relapsed or refractory peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and Validive, which completed Phase II clinical trial for the treatment of oral mucositis in patients treated for a head and neck cancer. Onxeo SA has a collaboration and licensing agreement with Spectrum Pharmaceuticals for the development of Beleodaq; a license agreement with Monopar Therapeutics Inc. to develop Validive; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as BioAlliance Pharma SA and changed its name to Onxeo SA in July 2014. Onxeo SA was founded in 1997 and is headquartered in Paris, France.

Corporate governance

Onxeo SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.